Astellas Pharma (4503) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic Vision and Value Creation

• Focus on turning innovative science into value for patients, prioritizing outcomes that matter and managing healthcare system costs.

• Emphasis on delivering patient-centered outcomes while managing healthcare costs.

Financial Performance and Strategic Growth

• FY 2024 revenue reached JPY 1.9 trillion ($13.1B) with a 20.5% operating profit margin; FY 2025 guidance targets JPY 2.0 trillion revenue and 24.1% margin.

• R&D expenses totaled JPY 328B ($2.26B), representing 17% of revenue.

• Over 85% of revenue is generated outside Japan, with operations in more than 70 countries.

• Dividend per share increased to JPY 74 ($0.51) in FY24.

Brand and Portfolio Strategy

• Five strategic brands (PADCEV, VYLOY, XOSPATA, IZERVAY, VEOZAH) are positioned to drive growth post-XTANDI exclusivity, with peak sales targets ranging from JPY 100B to JPY 500B.

• Deliberate strategy to offset XTANDI loss of exclusivity by building a diversified, majority fully owned, higher-margin portfolio.

• XTANDI achieved a 42% revenue CAGR (FY2012-2024) and is the most prescribed branded ARPI for advanced prostate cancer.

• Oncology now represents 75% of revenue, led by XTANDI, a $6B prostate cancer drug.

• Targeting a 30% operating profit margin by FY 2027, supported by cost optimization and financial discipline.